<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863145</url>
  </required_header>
  <id_info>
    <org_study_id>CB-03-10/01</org_study_id>
    <nct_id>NCT03863145</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors</brief_title>
  <official_title>Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cosmo Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cosmo Pharmaceuticals NV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will undergo baseline evaluation and an assessment of extent of disease.

      Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a
      modified Fibonacci schema using a standard oncology 3+3 study design to define an MTD and a
      RP2D. Plasma PK samples will be collected at predetermined timepoints for all subjects.

      Subjects in Part 2 (Dose Expansion) of the study will receive CB-03-10 at the RP2D determined
      in the Part 1 of the study. The indications included in each group will be determined at the
      completion of Part 1 of the study by Safety Review Committee (SRC).

      Subjects will be evaluated weekly initially (for 2 cycles in Part 1 and for 1 cycle in Part
      2) and every 2 weeks thereafter. Reassessment of disease will be conducted at Week 8 and
      every 8 weeks thereafter. Subjects with evidence of response (partial or complete) will be
      re-evaluated at least 4 weeks later for confirmation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo baseline evaluation and an assessment of extent of disease.

      Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a
      modified Fibonacci schema using a standard oncology 3+3 study design to define an MTD and a
      RP2D. Plasma PK samples will be collected at predetermined timepoints for all subjects.

      Subjects in Part 2 (Dose Expansion) of the study will receive CB-03-10 at the RP2D determined
      in the Part 1 of the study. The indications included in each group will be determined at the
      completion of Part 1 of the study by Safety Review Committee (SRC).

      Subjects will be evaluated weekly initially (for 2 cycles in Part 1 and for 1 cycle in Part
      2) and every 2 weeks thereafter. Reassessment of disease will be conducted at Week 8 and
      every 8 weeks thereafter. Subjects with evidence of response (partial or complete) will be
      re-evaluated at least 4 weeks later for confirmation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 (Dose Escalation): Subjects with advanced refractory solid tumors Part 2 (Dose Expansion): Defined subject subgroups considered likely to respond to CB-03-10 (eg, relapsed/refractory pancreatic adenocarcinoma, androgen independent prostate adenocarcinoma, triple-negative breast adenocarcinoma) or indications that demonstrated activity in Part 1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose</measure>
    <time_frame>30 days</time_frame>
    <description>Determine the maximum tolerated dose (MTD) of CB-03-10 in subjects with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the dose-limiting toxicity</measure>
    <time_frame>30 days</time_frame>
    <description>Determine the dose-limiting toxicity (DLT) of CB-03-10 in subjects with advanced solid tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine a recommended Phase 2 dose (RP2D) of CB-03-10</measure>
    <time_frame>30 days</time_frame>
    <description>Determine a recommended Phase 2 dose (RP2D) of CB-03-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>30 days</time_frame>
    <description>Determine the safety profile of CB-03-10 in subjects with advanced solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the activity response rate</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the activity response rate of CB-03-10 in subjects with specific solid tumors (eg, relapsed/refractory pancreatic adenocarcinoma, androgen independent prostate adenocarcinoma, relapsed/refractory triple-negative breast adenocarcinoma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CB-03-10</measure>
    <time_frame>30 days</time_frame>
    <description>Cmax of CB-03-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of CB-03-10</measure>
    <time_frame>30 days</time_frame>
    <description>AUC of CB-03-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of CB-03-10 metabolite CB-03-05</measure>
    <time_frame>30 days</time_frame>
    <description>Cmax of CB-03-10 metabolite CB-03-05</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of CB-03-10 metabolite CB-03-05</measure>
    <time_frame>30 days</time_frame>
    <description>AUC of CB-03-10 metabolite CB-03-05</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the activity overall survival [OS]</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the activity overall survival [OS] of CB-03-10 in subjects with specific solid tumors (eg, relapsed/refractory pancreatic adenocarcinoma, androgen independent prostate adenocarcinoma, relapsed/refractory triple-negative breast adenocarcinoma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the activity progression-free survival [PFS]</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the activity progression-free survival [PFS] of CB-03-10 in subjects with specific solid tumors (eg, relapsed/refractory pancreatic adenocarcinoma, androgen independent prostate adenocarcinoma, relapsed/refractory triple-negative breast adenocarcinoma)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Refractory Solid Tumors</condition>
  <condition>Subjects Considered Likely to Respond to CB-03-10</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 (Dose Escalation): 100 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-10</intervention_name>
    <description>CB-03-10, 100 mg capsule for oral use</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed, informed consent

          2. For Part 1 (Dose Escalation): Histologically or cytologically confirmed relapsed or
             refractory advanced or metastatic solid tumor of any origin, not amenable to standard
             of care therapy.

             For Part 2 (Dose Expansion): Histologically or cytologically confirmed relapsed or
             refractory advanced or metastatic solid tumor (specific tumor types to be determined
             by the Safety Review Committee (SRC) at the conclusion of Part 1, but will likely
             include one of the following 3 categories: advanced androgen independent prostate
             adenocarcinoma, relapsed/refractory pancreatic adenocarcinoma, or relapsed/refractory
             TNBC not amenable to standard of care therapies with reasonable likelihood of
             significant clinical benefit.

          3. Age: ≥ 18 years.

          4. ECOG performance status ≤ 2.

          5. For Part 1 (Dose Escalation) measurable or evaluable disease as per Response
             Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria For Part 2 (Dose Expansion):
             measurable disease as per RECIST 1.1 criteria

          6. Adequate hematology defined as:

               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               2. Platelets (PLT) ≥ 100 x 109/L

               3. Hemoglobin (Hb) ≥ 9.0 g/dl

          7. Adequate liver function defined as:

               1. Alanine aminotransferase (ALT) ≤ 3.0 x ULN (≤ 5 x the upper limit of normal [ULN]
                  if liver involved with tumor)

               2. Aspartate aminotransferase (AST) ≤ 3.0 x ULN (≤ 5 x ULN if liver involved with
                  tumor)

               3. Total bilirubin ≤ 1.5 mg/gL (except for subjects with Gilbert's syndrome in which
                  ≤ 3 x ULN)

          8. Adequate renal function defined as:

             a. Creatinine ≤ 1.5 ULN or creatinine clearance ≥ 50 mL/min

          9. If previously treated, recovered from adverse effects from prior therapy (eg,
             chemotherapy) to ≤ Grade 1 (graded according to National Cancer Institute [NCI] Common
             Terminology Criteria for Adverse Events, version 5.0 [CTCAE v.5.0]), except for the
             following:

             a. Alopecia (Grade 2 allowed)

         10. Negative pregnancy test for females of childbearing potential

         11. Commitment from subject to practice medically appropriate/acceptable method of birth
             control (eg, hormonal, condoms or other adequate barrier controls, intrauterine
             contraceptive device, or sterilization) beginning at the Screening Visit and
             continuing until 3 months following the last treatment with study drug

         12. Willingness and ability to comply with all study requirements

        Exclusion Criteria:

          1. Pregnancy or breastfeeding

          2. Presence of active infections (eg, requiring antimicrobial therapy) or other severe
             concurrent disease, which, in the opinion of the Investigator, would place the patient
             at undue risk or interfere with the study, and/or requiring systemic therapy.

          3. Positive hepatitis B core antibody or surface antigen unless quantitative DNA PCR is
             negative and subject will be receiving prophylaxis for reactivation

          4. Positive hepatitis C virus on PCR

          5. Positive HIV antibody

          6. Known brain metastases or signs and/or symptoms suggestive of brain metastases, spinal
             cord compression, carcinomatous meningitis, or leptomeningeal disease unless
             appropriately treated and neurologically stable for at least 4 weeks.

          7. Known cancer of other primary origin within the prior 5 years (excluding Stage I
             non-melanoma skin cancer and prostate cancer controlled with hormonal therapy)

          8. Active autoimmune disease (ie, requiring therapy or anticipated to require therapy
             while participating in study).

          9. Cardiac disease as manifested by any of the following:

               1. &gt; Grade II heart failure, graded per New York Heart Association (NYHA) criteria.

               2. Unstable angina pectoris

               3. Acute or subacute coronary syndromes, including myocardial infarction, occurring
                  within 1 year prior to study treatment

               4. Arrhythmia needing continuous treatment

               5. Ejection fraction less than the institutional lower limit of normal as assessed
                  by multigrated radionuclide angiography (MUGA) scan or echocardiogram

         10. Uncontrolled hypertension (ie, not on stable doses of antihypertensive medications for
             at least 1 month).

         11. Major surgery or trauma within 4 weeks prior to start of study treatment.

         12. Fewer than 28 days (or fewer than 5 half-lives, whichever is shorter) from prior
             anticancer therapy including chemotherapy, hormonal, investigational, and/or
             biological therapies except for ongoing hormonal therapy administered for control of
             cancer (eg, prostate cancer)

         13. Requirement for chronic corticosteroids or other immunosuppressant drugs. Limited use
             of corticosteroids to treat or prevent acute hypersensitivity reactions is not
             considered an exclusion criterion.

         14. Warfarin at doses greater than 1 mg/day or equivalent doses of other coumarin
             derivatives

         15. Participation in another interventional clinical trial

         16. Psychiatric illness/social situations that would interfere with compliance with study
             requirements

         17. Other severe medical or psychiatric conditions that would impart, in the judgement of
             the Investigator and/or Sponsor, excess risk to the subject during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://seer.cancer.gov/statfacts/html/esoph.html</url>
    <description>National Cancer Institute. Cancer of the Esophagus - SEER Stat Fact Sheets [Internet]. Cancer Statistics. 2015 [cited 2015 Sep 15].</description>
  </link>
  <link>
    <url>https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/E11-R1EWG_Step4_Addendum_2017_0818.pdf</url>
    <description>International Council on Harmonisation. Addendum to ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population e11(r1). Vol. Step 4, ICH Harmonised Guideline E11 (R1). 2017.</description>
  </link>
  <link>
    <url>http://www.ich.org/home.html</url>
    <description>International Conference on Harmonization Guidance on Good Clinical Practice [Internet]. [cited 2016 Jan 1].</description>
  </link>
  <results_reference>
    <citation>Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982 Mar;38(1):143-51.</citation>
    <PMID>7082756</PMID>
  </results_reference>
  <results_reference>
    <citation>Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.</citation>
    <PMID>21969517</PMID>
  </results_reference>
  <results_reference>
    <citation>Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.</citation>
    <PMID>24131140</PMID>
  </results_reference>
  <results_reference>
    <citation>Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep. 2013 Apr;15(2):182-9. doi: 10.1007/s11912-012-0290-4. Review.</citation>
    <PMID>23341367</PMID>
  </results_reference>
  <results_reference>
    <citation>Brower V. New approaches tackle rising pancreatic cancer rates. J Natl Cancer Inst. 2014 Dec 22;106(12). pii: dju417. doi: 10.1093/jnci/dju417. Print 2014 Dec.</citation>
    <PMID>25535299</PMID>
  </results_reference>
  <results_reference>
    <citation>Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14.</citation>
    <PMID>27300548</PMID>
  </results_reference>
  <results_reference>
    <citation>Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res. 2017 Mar 6;9:65-72. doi: 10.2147/CMAR.S124475. eCollection 2017.</citation>
    <PMID>28293120</PMID>
  </results_reference>
  <results_reference>
    <citation>Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep;138(3):656-62. doi: 10.1016/j.ygyno.2015.06.033. Epub 2015 Jun 24.</citation>
    <PMID>26115975</PMID>
  </results_reference>
  <results_reference>
    <citation>Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011 Oct 15;71(20):6360-70. doi: 10.1158/0008-5472.CAN-11-0362. Epub 2011 Aug 25.</citation>
    <PMID>21868756</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004 Mar 1;64(5):1757-64.</citation>
    <PMID>14996737</PMID>
  </results_reference>
  <results_reference>
    <citation>Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. Mol Cancer Ther. 2017 Aug;16(8):1680-1692. doi: 10.1158/1535-7163.MCT-16-0923. Epub 2017 Apr 20.</citation>
    <PMID>28428441</PMID>
  </results_reference>
  <results_reference>
    <citation>Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocr Relat Cancer. 2016 Jan;23(1):35-45. doi: 10.1530/ERC-15-0343. Epub 2015 Oct 19.</citation>
    <PMID>26483423</PMID>
  </results_reference>
  <results_reference>
    <citation>Yemelyanov A, Bhalla P, Yang X, Ugolkov A, Iwadate K, Karseladze A, Budunova I. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell Cycle. 2012 Jan 15;11(2):395-406. doi: 10.4161/cc.11.2.18945. Epub 2012 Jan 15.</citation>
    <PMID>22223138</PMID>
  </results_reference>
  <results_reference>
    <citation>Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 1;72(2):157-64. doi: 10.1002/pros.21416. Epub 2011 May 11.</citation>
    <PMID>21563193</PMID>
  </results_reference>
  <results_reference>
    <citation>Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, Culig Z, Van der Pluijm G, Klocker H. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. Clin Cancer Res. 2018 Feb 15;24(4):927-938. doi: 10.1158/1078-0432.CCR-17-0989. Epub 2017 Nov 20.</citation>
    <PMID>29158269</PMID>
  </results_reference>
  <results_reference>
    <citation>Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr;5(2):72-89. doi: 10.1007/s12672-014-0173-2. Epub 2014 Mar 11.</citation>
    <PMID>24615402</PMID>
  </results_reference>
  <results_reference>
    <citation>Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013 Dec 5;155(6):1309-22. doi: 10.1016/j.cell.2013.11.012.</citation>
    <PMID>24315100</PMID>
  </results_reference>
  <results_reference>
    <citation>Schweizer MT, Yu EY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015 Nov 13;8:128. doi: 10.1186/s13045-015-0225-2. Review.</citation>
    <PMID>26566796</PMID>
  </results_reference>
  <results_reference>
    <citation>Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.</citation>
    <PMID>29373071</PMID>
  </results_reference>
  <results_reference>
    <citation>Munoz J, Wheler JJ, Kurzrock R. Androgen receptors beyond prostate cancer: an old marker as a new target. Oncotarget. 2015 Jan 20;6(2):592-603. Review.</citation>
    <PMID>25595907</PMID>
  </results_reference>
  <results_reference>
    <citation>Robinson-Rechavi M, Escriva Garcia H, Laudet V. The nuclear receptor superfamily. J Cell Sci. 2003 Feb 15;116(Pt 4):585-6. Review.</citation>
    <PMID>12538758</PMID>
  </results_reference>
  <results_reference>
    <citation>Stringer EM, Saha P, Swoboda A, Kocherginsky M, Baker G, Olberkyte S, et al. A phase I trial of mifepristone (M), carboplatin (C), and gemcitabine (G) in advanced breast and ovarian cancer. J Clin Oncol. 2017;35 (15 sup(1083):1083.</citation>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

